Topic:

M&A

Latest Headlines

Latest Headlines

Baxter International gets Q2 infusion from acquisition of Swiss dialysis outfit

Baxter International is riding high off promising second-quarter earnings, numbers that the company largely attributes to its 2013 acquisition of Swiss dialysis heavyweight Gambro.

Ackman to Allergan shareholders: Valeant's offer won't last forever

Valeant may be offering $53 billion for Allergan now. But that bid might not be on the table by the time 2015 rolls around, Bill Ackman, head of Valeant takeover partner Pershing Square Capital Management, told the Botox maker's shareholders on a webcast Thursday.

Danaher adds to its diagnostics biz, but deal may not be large enough for the Street

Once known as a serial acquirer, Danaher broke its big acquisition drought with the addition of Siemen's clinical microbiology unit to its Beckman Coulter division. The price was not disclosed, but company officials described it as the largest deal in two years during the quarterly earnings call on the heels of the July 17 announcement. 

Novartis offloads share of LTS Lohmann to SAP billionaire Hopp, gaining $400M

For the past 8 months, Novartis and its partners have been trying to sell the skin-patch maker LTS Lohmann. Two private equity firms appeared ripe for a potential $1.7 billion deal. But that didn't happen. Now, Novartis and the German investment firm BWK are selling their shares in LTS to fellow owner Dietmar Hopp.

Pfizer joins crowd of companies snapping up sterile injectable players

Pfizer said Wednesday that it would buy New Jersey-based InnoPharma, for $225 million in cash and up to $135 million in contingent milestone payments.

Pfizer and Sun snatch up sterile injectable companies to boost expertise and capacity

The sterile injectables business holds promise for drugmakers with the manufacturing capabilities to produce the difficult-to-make drugs. Deals announced Wednesday by Pfizer and Sun Pharma were proof positive of how companies think they can cash in on the generics piece of this sterile injectables market.

'Economic patriotism' could dampen biopharma's M&A boom

The fervor over American companies merging with overseas rivals to lower their tax rates has drawn the ire of the Obama Administration, possibly imperiling the so-called inversion deals that have become increasingly popular in biopharma.

Dublin-based Perrigo could be up next for a tax-inversion deal

OTC generics maker Perrigo could be the next tax-advantaged company in line for a buyout. And while Perrigo hasn't confirmed any M&A plans, speculation has been enough to send shares soaring.

Abbott CEO: 'I don't feel the pressure to invert'

Wall Street analysts took advantage of a conference call on Abbott's just-announced sale of its developed market generics business to ask about some of their favorite topics, future M&A and the recent onset of  tax inversion mania among life science companies. 

St. Jude shells out $200M for chronic pain therapy manufacturer NeuroTherm

St. Jude Medical signed on the dotted line to acquire interventional pain management therapy manufacturer NeuroTherm for approximately $200 million in cash, strengthening its foothold in the chronic pain market.